- Pharmaxis (PXS) has exported the first shipment of its locally developed and manufactured drug, Bronchitol, to Georgia, USA
- The Bronchitol treatment has approved in the U.S. and Australia for adults and children suffering with cystic fibrosis
- Cystic fibrosis (CF) is a debilitating genetic disease that causes damage to the lungs and other organs
- The company expects Bronchitol sales in the U.S. to contribute strongly to the product’s overall sales and profit growth
- Chiesi Group, will responsible for the commercialisation of Bronchitol in the U.S
- Pharmaxis is up 3.41 per cent, trading at 9.1 cents
